NCT04419363

Burosumab in Children and Adolescents With X-linked Hypophosphatemia

12-months of Treatment With Burosumab in Children and Adolescents With X-linked Hypophosphatemia: a Prospective Longitudinal Cohort Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 57 (estimated)
• Sponsor: Bicetre Hospital · Academic / Other
• Sex: All
• Age: 1 Year – 20 Years
• Healthy volunteers: Not accepted

Summary

In this prospective longitudinal cohort study we studied the efficacy and safety of burosumab in real-clinical practice for \<13- and \>13-years old children affected with X-linked hypophosphatemia. 57 children with XLH were switched from conventional treatment to burosumab. After 12 months we assessed the efficacy and safety of treatment with burosumab on the whole cohort and separately on the cohort of \>13-years old adolescents.

Conditions

• Rare Diseases
• X-linked Hypophosphatemia

Interventions

Type	Name	Description
DRUG	Burosumab Injection	Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab

Timeline

• Start date: 2018-03-18
• Primary completion: 2019-03-20
• Completion: 2022-09-16
• First posted: 2020-06-05
• Last updated: 2020-06-05

Locations

1 site across 1 country: France